Home > Oncology > SABCS 2019 > Phase 2 Trial Update > HER2 antibody-drug conjugate T-DXd promising in T-DM1 pretreated patients

HER2 antibody-drug conjugate T-DXd promising in T-DM1 pretreated patients

Conference
SABCS 2019
Trial
Phase 2, DESTINY-Breast01

Results from the phase 2 clinical trial DESTINY-Breast01 showed that the investigational human epidermal growth factor receptor 2 (HER2)-targeted antibody-drug conjugate [Fam-] trastuzumab deruxtecan (T-DXd) has durable objective responses in patients with HER2-positive breast cancer who were heavily pretreated. Although T-DXd had a generally manageable safety profile, interstitial lung disease (ILD) was identified as a risk warranting proactive awareness and management.

Despite the fact that HER2-directed therapies like trastuzumab, pertuzumab, and T-DM1 have led to improved outcomes for patients with HER2-positive advanced breast cancer, resistance to these drugs is almost inevitable. Once patients develop resistance, it is not clear what treatment should be given, highlighting the unmet medical need for new and improved therapies for these patients. T-DXd is an antibody-drug conjugate with an HER2 antibody, peptide-based cleavable linker, and a novel topoisomer...



please login to read the entire article:


You need to register to read the entire article, please do so now.





Posted on